#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	19	16292	16S	1529	1529	100.0	16S.l6.c4.ctg.1	2142	755.9	1	SNP	n	C1184T	0	.	.	1184	1184	C	1423	1423	C	958	C	897	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29944	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3482	856.7	0	.	n	.	0	T695C	SNP	695	695	T	1013	1013	C	964	C,G	895,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29944	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3482	856.7	0	.	n	.	0	G1337A	SNP	1337	1337	G	1655	1655	A	978	A	921	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29944	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3482	856.7	0	.	n	.	0	T1971C	SNP	1971	1971	T	2289	2289	C	923	C	876	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29944	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3482	856.7	1	SNP	n	C2597T	1	C2597T	SNP	2597	2597	C	2915	2915	T	906	T,C	658,208	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29944	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3482	856.7	1	SNP	n	A2045G	0	.	.	2045	2045	A	2363	2363	A	1006	A	940	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	29944	23S	2890	2890	99.86	23S.l15.c4.ctg.1	3482	856.7	0	HET	.	.	.	C265T,G	.	265	265	C	583	583	C	936	C,T,G	566,206,1	.	.
folP.WHO_O_01412c	folP.WHO_O_01412c	1	1	27	2252	folP	855	855	100.0	folP.l6.c4.ctg.1	1619	138.7	1	SNP	p	R229S	1	.	.	685	687	AGC	1029	1031	AGC	251;247;251	A;G;C	238;233;238	folP.WHO_O_01412c:1:1:R229S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6066	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3327	181.5	1	SNP	p	S91F	0	.	.	271	273	TCC	515	517	TCC	191;193;194	T;C;C	178;179;180	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6066	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3327	181.5	1	SNP	p	D95G	0	.	.	283	285	GAC	527	529	GAC	189;189;186	G;A;C	175;177;174	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	6066	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3327	181.5	1	SNP	p	D95N	0	.	.	283	285	GAC	527	529	GAC	189;189;186	G;A;C	175;177;174	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1251	141.2	0	.	p	.	0	A39T	NONSYN	115	117	GCC	413	415	ACC	199;204;204	A,G;C;C	180,1;190;188	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1251	141.2	0	.	p	.	0	R44H	NONSYN	130	132	CGC	428	430	CAC	194;196;197	C;A,G;C	179;177,1;183	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1251	141.2	0	.	p	.	0	Y105H	NONSYN	313	315	TAC	611	613	CAC	245;247;246	C;A;C	227;226;230	.	.
mtrR.WHO_G_01393	mtrR.WHO_G_01393	1	1	539	1774	mtrR	633	633	99.21	mtrR.l15.c17.ctg.1	1251	141.2	1	SNP	p	G45D	0	.	.	133	135	GGC	431	433	GGC	194;194;196	G;G,A;C	178;178,1;179	mtrR.WHO_G_01393:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	19	1024	mtrR_promoter	250	250	100.0	mtrR_promoter.l15.c4.ctg.1	1067	95.7	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5948	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	200.1	1	SNP	p	D86N	0	.	.	256	258	GAC	544	546	GAC	249;248;250	G;A;C	232;228;235	parC.WHO_P_00203c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5948	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	200.1	1	SNP	p	S87W	0	.	.	259	261	AGT	547	549	AGT	252;251;252	A;G;T,C	231;235;233,1	parC.WHO_P_00203c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5948	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	200.1	1	SNP	p	S87I	0	.	.	259	261	AGT	547	549	AGT	252;251;252	A;G;T,C	231;235;233,1	parC.WHO_P_00203c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5948	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	200.1	1	SNP	p	S87R	0	.	.	259	261	AGT	547	549	AGT	252;251;252	A;G;T,C	231;235;233,1	parC.WHO_P_00203c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_P_00203c	parC.WHO_P_00203c	1	1	27	5948	parC	2304	2304	100.0	parC.l15.c4.ctg.1	2965	200.1	1	SNP	p	S88P	0	.	.	262	264	TCC	550	552	TCC	251;252;253	T,C;C;C	237,1;236;237	parC.WHO_P_00203c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4952	parE	1986	1986	100.0	parE.l6.c30.ctg.1	2810	175.8	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1668	1670	GGC	244;241;238	G;G;C	225;222;221	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	A311V	0	.	.	931	933	GCA	1184	1186	GCA	244;243;241	G;C;A	220;218;220	penA.2.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	I312M	0	.	.	934	936	ATC	1187	1189	ATC	241;245;249	A;T;C	222;227;230	penA.2.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	V316T	0	.	.	946	948	GTG	1199	1201	GTG	247;244;243	G;T;G	227;221;225	penA.2.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	V316P	0	.	.	946	948	GTG	1199	1201	GTG	247;244;243	G;T;G	227;221;225	penA.2.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1703	1705	ACC	246;247;246	A;C;C	226;234;232	penA.2.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	A502P	0	.	.	1504	1506	GCG	1757	1759	GCG	242;237;235	G;C,G;G	205;186,2;191	penA.2.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	A502V	0	.	.	1504	1506	GCG	1757	1759	GCG	242;237;235	G;C,G;G	205;186,2;191	penA.2.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	G543S	0	.	.	1627	1629	GGC	1880	1882	GGC	183;181;181	G;G;C,T	174;171;172,1	penA.2.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	G546S	0	.	.	1636	1638	GGC	1889	1891	GGC	181;180;177	G,A;G;C	164,2;163;162	penA.2.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.2.001	penA.2.001	1	1	27	4362	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2182	197.8	1	SNP	p	P552S	0	.	.	1654	1656	CCG	1907	1909	CCG	155;155;154	C,CGG;C,G;GCCC,GGCCCC	112,1;113,2;105,1	penA.2.001:1:1:P552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	6170	ponA	2397	2397	100.0	ponA.l6.c30.ctg.1	3155	195.0	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1612	1614	CCG	209;210;209	C;C;G	189;196;189	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2556	porA	1146	1146	99.83	porA.l15.c4.ctg.1	1749	145.0	0	.	p	.	0	M83fs	FSHIFT	247	247	A	492	492	C	197	C	183	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	T18M	NONSYN	52	54	ACG	338	340	ATG	190;192;193	A;T;G	178;179;180	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	E41K	NONSYN	121	123	GAA	407	409	AAA	216;217;216	A;A;A	202;204;201	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	E48G	NONSYN	142	144	GAA	428	430	GGA	226;229;232	G;G;A,T	210;213;212,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	V75I	NONSYN	223	225	GTT	509	511	ATT	231;233;232	A;T;T	213;219;216	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	T87A	NONSYN	259	261	ACT	545	547	GCT	229;229;231	G;C;T	211;213;211	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	T89S	NONSYN	265	267	ACC	551	553	AGC	230;228;227	A;G;C	209;208;205	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	V98I	NONSYN	292	294	GTC	578	580	ATC	238;236;236	A;T;C	216;214;214	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	.	MULTIPLE	358	359	AA	643	644	CG	215;215	C;G,A	207;198,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	.	MULTIPLE	361	362	GA	646	648	CAG	214;209;210	C,G;A;G,A	202,2;201;198,3	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	N122K	NONSYN	364	366	AAC	650	652	AAA	211;214;214	A;A;A,C	204;207;204,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	F131Y	NONSYN	391	393	TTT	677	679	TAT	213;214;212	T;A,T;T	207;206,2;201	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	N134E	NONSYN	400	402	AAT	686	688	GAG	216;217;218	G,A;A;G,T	205,2;209;206,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	V135F	NONSYN	403	405	GTG	689	691	TTT	216;217;218	T,G;T;T,G	199,2;208;207,2	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	G140K	NONSYN	418	420	GGA	704	706	AAA	196;195;197	A,G;A,G;A	186,1;187,1;189	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	K143E	NONSYN	427	429	AAA	713	715	GAA	201;203;201	G,C;A;A	186,1;189;188	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	V151A	NONSYN	451	453	GTA	737	739	GCA	220;224;227	G,A;C;A	204,1;209;210	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	T213S	NONSYN	637	639	ACA	923	925	TCA	239;238;240	T;C,T;A	230;228,1;230	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	G253Q	NONSYN	757	759	GGA	1043	1045	CAA	204;203;202	C,A;A;A	195,1;199;199	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	.	INDELS	760	762	ACA	1047	1051	ATCAA	202;201;201;202;202	A;T;C;A;A	198;195;195;198;198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	.	INDELS	763	764	TG	1054	1056	AGT	201;199;203	A;G;T	197;195;198	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	A257D	NONSYN	769	771	GCT	1061	1063	GAT	203;203;201	G;A;T	200;199;197	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	T269S	NONSYN	805	807	ACC	1097	1099	AGC	205;204;204	A;G;C,T	199;199;197,1	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	D293S	NONSYN	877	879	GAT	1169	1171	AGT	257;254;254	A;G;T	240;238;239	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	N295D	NONSYN	883	885	AAC	1175	1177	GAC	258;259;257	G;A;C	242;242;241	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	0	.	p	.	0	H296Y	NONSYN	886	888	CAC	1178	1180	TAC	258;261;260	T;A;C	243;244;246	.	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	1	SNP	p	G120K	1	.	.	358	360	AAG	643	645	CGG	215;215;216	C;G,A;G,A	207;198,2;206,2	porB1b.WHO_M_02204c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	1	SNP	p	D121N	0	.	.	361	363	GAC	646	649	CGC	214;210;211	C,G;G,A;C	202,2;198,3;202	porB1b.WHO_M_02204c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_M_02204c	porB1b.WHO_M_02204c	1	1	539	2812	porB1b	1041	1041	96.09	porB1b.l15.c4.ctg.1	1465	189.8	1	SNP	p	A121D	1	.	.	361	363	GAC	646	649	CGC	214;210;211	C,G;G,A;C	202,2;198,3;202	porB1b.WHO_M_02204c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_M_02157	rpoB.WHO_M_02157	1	1	27	11382	rpoB	4179	4179	100.0	rpoB.l15.c17.ctg.1	4797	236.8	1	SNP	p	H553N	1	.	.	1657	1659	AAT	1961	1963	AAT	254;255;254	A;A;T	234;234;234	rpoB.WHO_M_02157:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1208	rpsJ	312	312	100.0	rpsJ.l15.c17.ctg.1	979	122.7	1	SNP	p	V57M	1	.	.	169	171	ATG	462	464	ATG	244;249;250	A;T;G	230;234;236	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
